Self-assembling peptide nanofibers decorated with targeting and cell-penetrating peptides delivered doxorubicin to triple-negative breast cancer cells with equal antiproliferative effect at just 7.5 µM versus 50 µM of free drug, while showing no toxicity to healthy cells.
6.7x dose reductionPeptide nanofiber carrying 7.5 µM doxorubicin achieved the same antiproliferative effect on TNBC cells as 50 µM of free doxorubicin
What the researchers found
The peptide nanofiber (NF-Dox) achieved complete internalization into TNBC cells (MDA-MB 231) within 1 hour, primarily through a translocation mechanism mediated by gH625. The antiproliferative effect of NF-Dox carrying 7.5 µM doxorubicin was equivalent to 50 µM free doxorubicin — a ~6.7-fold dose reduction. The empty carrier (NF) showed no toxicity to either healthy keratinocytes (HaCaT) or TNBC cells. The nanofiber was 250 nm long, 10 nm in diameter, and stable across varying dilution, ionic strength, and pH conditions.
The on-demand drug release was achieved through an MMP-9-cleavable linker, ensuring doxorubicin was only released in the tumor microenvironment where MMP-9 is overexpressed.
Why it matters
Triple-negative breast cancer has the worst prognosis of all breast cancer subtypes and few targeted therapies. Doxorubicin is effective but causes severe side effects (especially heart damage) due to its non-selective distribution. This peptide nanofiber platform achieves the same cancer-killing effect at dramatically lower doses, potentially reducing the devastating side effects that limit doxorubicin use.
How the study worked
Amphiphilic peptides were designed to self-assemble into nanofibers decorated with three functional moieties: the cell-penetrating peptide gH625, the EGFR-targeting peptide P22, and doxorubicin linked via an MMP-9-cleavable sequence. Physicochemical characterization included size, stability, and morphology analysis. Biological testing included cellular uptake (internalization kinetics and mechanism), cytotoxicity against TNBC (MDA-MB 231) and healthy cells (HaCaT), and antiproliferative assays comparing NF-Dox to free doxorubicin.
What this study cannot tell us
All experiments were in vitro using cell lines; no animal tumor models were tested. The study used a single TNBC cell line (MDA-MB 231), and results may differ with other TNBC subtypes. In vivo biodistribution, pharmacokinetics, immune response, and tumor accumulation were not assessed. Manufacturing scalability and reproducibility of the self-assembly process at larger scales are unknown.
How to read the evidence
This is a preclinical in vitro study demonstrating proof-of-concept for a novel peptide-based drug delivery platform. The physicochemical and cellular characterization is thorough, but without in vivo data, the clinical translational potential remains uncertain.
When this study was published
Published in 2024, this is recent work at the cutting edge of peptide nanomedicine for cancer drug delivery.
The bigger picture
This study represents the frontier of peptide-based nanomedicine: using peptides not just as drugs but as the structural backbone of a multi-functional delivery system. The modular design — swappable targeting, penetration, and drug release components — makes this a versatile platform that could be adapted for other cancers and drugs, demonstrating the engineering potential of self-assembling peptides.
Questions still open
- Does the nanofiber maintain its 6.7x dose advantage in animal tumor models with full immune systems and tumor microenvironments?
- Could this platform be adapted for other chemotherapy drugs beyond doxorubicin?
- How does the MMP-9-dependent release perform in tumors with variable MMP-9 expression levels?
Common questions
How does the nanofiber know to release the drug only at the tumor?
Why is a 6.7x dose reduction important for cancer treatment?
Read the original research
Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.
International journal of nanomedicine, 19, 6057-6084
Citation
Bellavita, Rosa; Piccolo, Marialuisa; Leone, Linda; Ferraro, Maria Grazia; Dardano, Principia; De Stefano, Luca; Nastri, Flavia; Irace, Carlo; Falanga, Annarita; Galdiero, Stefania. (2024). Tuning Peptide-Based Nanofibers for Achieving Selective Doxorubicin Delivery in Triple-Negative Breast Cancer.. International journal of nanomedicine, 19, 6057-6084. https://doi.org/10.2147/IJN.S453958